N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

McCallum, Matthew, De Marco, Anna, Lempp, Florian A., Tortorici, M. Alejandra, Pinto, Dora, Walls, Alexandra C., Beltramello, Martina, Chen, Alex +26 more·2021·Cell
DOI 10.1016/j.cell.2021.03.028

Cited by (909)

Items 301–400 of 909

  1. SARS-CoV-2–specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies
    Anna Jeffery-Smith, Alice R. Burton, Sabela Lens, Chloe Rees-Spear, Jessica E. Davies, Monika Patel, Robin Gopal, Luke Muir, Felicity Aiano, Katie J. Doores et al. · 2022 · DOAJ (DOAJ: Directory of Open Access Journals)
  2. Proteases and variants: context matters for SARS-CoV-2 entry assays
    Christian S. Stevens, Kasopefoluwa Y. Oguntuyo, Benhur Lee · 2021 · Current Opinion in Virology
  3. Immune Evasion of SARS-CoV-2 Omicron Subvariants
    Hanzhong Ke, Matthew Chang, Wayne Anthony Marasco · 2022 · Vaccines
  4. Structural understanding of SARS-CoV-2 virus entry to host cells
    Kim Phuong Uyen Le, Shrute Kannappan, Truc Kim, Jung Heon Lee, Hye-Ra Lee, Kyeong Kyu Kim · 2023 · Frontiers in Molecular Biosciences
  5. Structural Immunology of SARS ‐ CoV ‐2
    Meng Yuan, Ian A. Wilson · 2024 · Immunological Reviews
  6. Three-Dimensional Visualization of Viral Structure, Entry, and Replication Underlying the Spread of SARS-CoV-2
    James W. Saville, Alison Berezuk, Shanti Swaroop Srivastava, Sriram Subramaniam · 2022 · Chemical Reviews
  7. A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core
    Rui Shi, Jiawei Zeng, Ling Xu, Fengze Wang, Xiaomin Duan, Yue Wang, Zheng Wu, Dandan Yu, Qingrui Huang, Yong‐Gang Yao et al. · 2022 · EBioMedicine
  8. Electrostatic Surface Potential as a Key Parameter in Virus Transmission and Evolution: How to Manage Future Virus Pandemics in the Post-COVID-19 Era
    Jacques Fantini, Fodil Azzaz, Henri Chahinian, Nouara Yahi · 2023 · Viruses
  9. Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera
    Geoffrey B. Hutchinson, Olubukola M. Abiona, Cynthia T. Ziwawo, Anne P. Werner, Daniel Ellis, Yaroslav Tsybovsky, Sarah R. Leist, Charis Palandjian, Ande West, Ethan J. Fritch et al. · 2023 · Nature Communications
  10. COVID-19 vaccines dampen genomic diversity of SARS-CoV-2: Unvaccinated patients exhibit more antigenic mutational variance
    Michiel J.M. Niesen, Praveen Anand, Eli Silvert, Rohit Suratekar, Colin Pawlowski, Pritha Ghosh, Patrick J. Lenehan, Travis K. Hughes, David Zemmour, John Charles O’Horo et al. · 2021 · medRxiv
  11. Structure-activity relationships of B.1.617 and other SARS-CoV-2 spike variants
    Tzu‐Jing Yang, Pei‐Yu Yu, Yuan‐Chih Chang, Ning-En Chang, Yu-Xi Tsai, Kang-Hao Liang, Piotr Drączkowski, Bertina Lin, Yongsheng Wang, Yu-Chun Chien et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  12. Defining neutralization and allostery by antibodies against COVID-19 variants
    Nikhil Kumar Tulsian, Palur Venkata Raghuvamsi, Xinlei Qian, Yue Gu, Bhuvaneshwari D O Shunmuganathan, Firdaus Samsudin, Yee Hwa Wong, Jianqing Lin, Kiren Purushotorman, Mary Kozma et al. · 2023 · Nature Communications
  13. Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution
    Ida Monrad, Signe Risgaard Sahlertz, Stine Sofie Frank Nielsen, Louise Ørnskov Pedersen, Mikkel Steen Petersen, Carl Mathias Kobel, Irene Harder Tarpgaard, Merete Storgaard, Klaus Leth Mortensen, Mariane Høgsbjerg Schleimann et al. · 2021 · Open Forum Infectious Diseases
  14. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19
    Yu Kaku, Takeo Kuwata, Hasan Md Zahid, Takao Hashiguchi, Takeshi Noda, Noriko Kuramoto, Shashwata Biswas, Kaho Matsumoto, Mikiko Shimizu, Yoko Kawanami et al. · 2021 · Cell Reports
  15. Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations
    William M. Showers, Sonia M. Leach, K. Kechris, M. Strong · 2021 · Infection, Genetics and Evolution
  16. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries
    Tom Z. Yuan, P. Garg, Linya Wang, Jordan R. Willis, Eric Kwan, Ana G. Lujan Hernandez, Emily Tuscano, Emily N Sever, Erica Keane, Cinque S. Soto et al. · 2021 · mAbs
  17. Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants
    Isabelle Montgomerie, Thomas W. Bird, Olga Rose Palmer, Ngarangi C. Mason, Theresa E. Pankhurst, Blair Lawley, Leonor C. Hernández, Rhodri Harfoot, Astrid Authier-Hall, Danielle E. Anderson et al. · 2023 · iScience
  18. An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies
    Lucia Spicuzza, Davide Campagna, Chiara Di Maria, Enrico Sciacca, Salvatore Mancuso, Carlo Vancheri, Gianluca Sambataro · 2023 · AIMS Microbiology
  19. A novel variant of interest of SARS-CoV-2 with multiple spike mutations detected through travel surveillance in Africa
    Túlio de Oliveira, Silvia Lutucuta, John N. Nkengasong, Joana F. M. Morais, Joana Paixão, Zoraima Neto, Pedro Afonso, Julio Miranda, Kumbelembe David, Luzia Inglês et al. · 2021 · medRxiv
  20. Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
    Günl, Franziska, Mecate-Zambrano, Angeles, Rehländer, Selina, Hinse, Saskia, Ludwig, Stephan, Brunotte, Linda · 2021 · Vaccines
  21. Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
    Graham, Carl, Seow, Jeffrey, Huettner, Isabella, Khan, Hataf, Kouphou, Neophytos, Acors, Sam, Winstone, Helena, Pickering, Suzanne, Galao, Rui Pedro, Lista, Maria Jose et al. · 2021
  22. Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study
    Susan Jackson, Julia L. Marshall, Andrew Mawer, Raquel Lopez Ramon, Stephanie A. Harris, Iman Satti, Eileen Hughes, Hannah Preston-Jones, Ingrid Cabrera Puig, Stéphanie Longet et al. · 2024 · The Lancet Microbe
  23. Combination of S1–N–Terminal and S1–C–Terminal Domain Antigens Targeting Double Receptor-Binding Domains Bolsters Protective Immunity of a Nanoparticle Vaccine against Porcine Epidemic Diarrhea Virus
    Dan Yang, Mingjun Su, Donghua Guo, Feiyu Zhao, Meijiao Wang, Jiaying Liu, Jingxuan Zhou, Yingming Sun, Xu Yang, Shanshan Qi et al. · 2024 · ACS Nano
  24. Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies
    Claudia Pommerenke, Ulfert Rand, Cord C. Uphoff, Stefan Nagel, Margarete Zaborski, Vivien Hauer, Maren Kaufmann, Corinna Meyer, Sabine A. Denkmann, Peggy Riese et al. · 2021 · PLoS ONE
  25. Anti-SARS-CoV-1 and −2 nanobody engineering towards avidity-inspired therapeutics
    Eugene Marfo Obeng, Christian K. O. Dzuvor, Michael K. Danquah · 2021 · Nano Today
  26. Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
    Lianlian Bian, Jianyang Liu, Fan Gao, Qiushuang Gao, Qian He, Qunying Mao, Xing Wu, Miao Xu, Zhenglun Liang · 2022 · Human Vaccines & Immunotherapeutics
  27. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
    Mengqi Yuan, Xiangyu Chen, Yanzhi Zhu, Xiaoqing Dong, Yan Liu, Zhaohui Qian, Lilin Ye, Pinghuang Liu · 2022 · Journal of Virology
  28. Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning
    Wenhao O. Ouyang, Timothy J.C. Tan, Ruipeng Lei, Ge Song, Collin Kieffer, Raiees Andrabi, Kenneth A. Matreyek, Nicholas C. Wu · 2022 · Science Advances
  29. Longitudinal single-cell analysis of SARS-CoV-2–reactive B cells uncovers persistence of early-formed, antigen-specific clones
    Lydia Scharf, Hannes Axelsson, Aikaterini Emmanouilidi, Nimitha R. Mathew, Daniel J. Sheward, Susannah Leach, Pauline Isakson, Ilya Valerevich Smirnov, Emelie Marklund, Nicolae Miron et al. · 2022 · JCI Insight
  30. Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV
    Vitaliy A. Matveev, Erik Z. Mihelic, Erika Benko, Patrick Budylowski, Sebastian Grocott, Terry Lee, Chapin S. Korosec, Karen Colwill, Henry Stephenson, Ryan Law et al. · 2023 · iScience
  31. S glycoprotein diversity of the Omicron variant
    Rakesh Sarkar, Mahadeb Lo, Ritubrita Saha, Shanta Dutta, Mamta Chawla‐Sarkar · 2021 · medRxiv
  32. The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes
    Allison J. Greaney, Rachel T. Eguia, Tyler N. Starr, Khadija Khan, Nicholas Franko, Jennifer K. Logue, Sandra M. Lord, Cate Speake, Helen Y. Chu, Alex Sigal et al. · 2022 · PLoS Pathogens
  33. The mechanisms of immune response and evasion by the main SARS-CoV-2 variants
    Qiuli Chen, Jiawei Zhang, Peter Wang, Zuyong Zhang · 2022 · iScience
  34. Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies
    F. Lempp, Leah B. Soriaga, Martin Montiel-Ruiz, F. Benigni, Julia Noack, Young-Jun Park, S. Bianchi, A. Walls, J. Bowen, Jia-Yi Zhou et al. · 2021 · bioRxiv
  35. An overview of methods for the structural and functional mapping of epitopes recognized by anti-SARS-CoV-2 antibodies
    I. Francino-Urdaniz, T. Whitehead · 2021 · RSC Chemical Biology
  36. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants
    Wei‐Shuo Lin, I-Chen Chen, Hui‐Chen Chen, Yi‐Chien Lee, Suh‐Chin Wu · 2021 · Frontiers in Immunology
  37. Antibody-mediated immunity to SARS-CoV-2 spike
    John M. Errico, Lucas J. Adams, Daved H. Fremont · 2022 · Advances in immunology
  38. SARS-CoV-2 before and after Omicron: two different viruses and two different diseases?
    Renata Gili, Roberto Burioni · 2023 · Journal of Translational Medicine
  39. Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope
    Efi Makdasi, Y. Levy, R. Alcalay, Tal Noy-Porat, E. Zahavy, A. Mechaly, E. Epstein, Eldar Peretz, H. Cohen, L. Bar-On et al. · 2021 · Viruses
  40. Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants
    Amin Addetia, Luca Piccoli, James Brett Case, Young‐Jun Park, Martina Beltramello, Barbara Guarino, Ha V. Dang, Dora Pinto, Suzanne M. Scheaffer, Kaitlin R. Sprouse et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  41. Immune evasion of SARS-CoV-2 variants of concern is driven by low affinity to neutralizing antibodies
    Matheus Vitor Ferreira Ferraz, Emerson Gonçalves Moreira, Danilo F. Coêlho, Gabriel Luz Wallau, Roberto Dias Lins · 2021 · Chemical Communications
  42. Uncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibody
    Ting-Yi Li, H. Cai, Ya-Pei Zhao, Yanfang Li, Y. Lai, H. Yao, Liu Daisy Liu, Zhou Sun, Martje Fentener van Vlissingen, T. Kuiken et al. · 2021 · EMBO Molecular Medicine
  43. Natural SARS-CoV-2 Infection Affects Neutralizing Activity in Saliva of Vaccinees
    Micaela Garziano, Olga Utyro, Mariacristina Poliseno, Teresa Antonia Santantonio, Irma Saulle, Sergio Strizzi, Sergio Lo Caputo, Mario Clerici, Andrea Introini, Mara Biasin · 2022 · Frontiers in Immunology
  44. Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display
    Shiho Tanaka, C. Anders Olson, Christopher O. Barnes, Wendy Higashide, Marcos R. Gonzalez, Justin D. Taft, Ashley Richardson, Marta Martín-Fernández, Dusan Bogunovic, Priyanthi N.P. Gnanapragasam et al. · 2022 · Cell Reports
  45. Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection
    Elham Khatamzas, Markus H. Antwerpen, Alexandra Rehn, Alexander Graf, Johannes C. Hellmuth, Alexandra Hollaus, Anne‐Wiebe Mohr, Erik Gaitzsch, Tobias Weiglein, Enrico Georgi et al. · 2022 · Nature Communications
  46. A comprehensive update on CIDO: the community-based coronavirus infectious disease ontology
    Yongqun Oliver He, Hong Jie Yu, Anthony Huffman, Yu Lin, Darren A. Natale, John R. Beverley, Ling Zheng, Yehoshua Perl, Zhigang Wang, Yingtong Liu et al. · 2022 · Journal of Biomedical Semantics
  47. Biology of the SARS-CoV-2 Coronavirus
    Rimma N. Mingaleeva, Nigina A. Nigmatulina, Liliya M. Sharafetdinova, Albina M. Romozanova, Aida G. Gabdoulkhakova, Филина Юлия Викторовна, Шавалиев Рафаэль Фирнаялович, Albert Anatolyevich Rizvanov, Мифтахова Регина Рифкатовна · 2022 · Biochemistry (Moscow)
  48. Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail
    Amin Addetia, Young‐Jun Park, Tyler N. Starr, Allison J. Greaney, Kaitlin R. Sprouse, John E. Bowen, Sasha W. Tilles, Wesley C. Van Voorhis A, Jesse D. Bloom, Davide Corti et al. · 2023 · Cell Reports
  49. Dominant clade‐featured SARS‐CoV‐2 co‐occurring mutations reveal plausible epistasis: An in silico based hypothetical model
    A. S. M. Rubayet Ul Alam, Ovinu Kibria Islam, Md. Shazid Hasan, Mir Raihanul Islam, Shafi Mahmud, Hassan M. Al‐Emran, Iqbal Kabir Jahid, Keith A. Crandall, M. Anwar Hossain · 2021 · Journal of Medical Virology
  50. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
    Yandi Zhang, Jo‐Lewis Banga Ndzouboukou, Mengze Gan, Xiaosong Lin, Xionglin Fan · 2021 · Frontiers in Immunology
  51. Prefusion spike protein conformational changes are slower in SARS-CoV-2 than in SARS-CoV-1
    Vivek Govind Kumar, Dylan S. Ogden, Ugochi H. Isu, Adithya Polasa, James Losey, Mahmoud Moradi · 2022 · Journal of Biological Chemistry
  52. Development of antibody resistance in emerging mutant strains of SARS CoV‐2: Impediment for COVID‐19 vaccines
    Narasimha Murthy Beeraka, Olga A. Sukocheva, Elena Lukina, Junqi Liu, Ruitai Fan · 2022 · Reviews in Medical Virology
  53. SCORe: SARS-CoV-2 Omicron variant RBD-binding DNA aptamer for multiplexed rapid detection and pseudovirus neutralization
    Lucy F. Yang, N. Kacherovsky, J. Liang, S. Salipante, Suzie H. Pun · 2022 · Analytical Chemistry
  54. Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals
    M. Jaago, Annika Rähni, N. Pupina, A. Pihlak, H. Sadam, Jürgen Tuvikene, A. Avarlaid, A. Planken, M. Planken, L. Haring et al. · 2022 · Scientific Reports
  55. Coordinated evolution at amino acid sites of SARS-CoV-2 spike
    Alexey D. Neverov, Gennady G. Fedonin, Anfisa V. Popova, Daria Bykova, Georgii A. Bazykin · 2023 · eLife
  56. An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination
    Juan Manuel Carreño, Ariel J. Raskin, Gagandeep Singh, Johnstone Tcheou, Hisaaki Kawabata, Charles Gleason, Komal Srivastava, Vladimir I. Vigdorovich, Nicholas Dambrauskas, Sneh Lata Gupta et al. · 2023 · Science Translational Medicine
  57. Mutations in S2 subunit of SARS-CoV-2 Omicron spike strongly influence its conformation, fusogenicity, and neutralization sensitivity
    Sahil Kumar, Rathina Delipan, Debajyoti Chakraborty, Kawkab Kanjo, Randhir Singh, Nittu Singh, S. Siddiqui, A. Tyagi, V. Jha, K. Thakur et al. · 2023 · bioRxiv
  58. A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines
    Lee, Jimin, Stewart, Cameron, Schäfer, Alexandra, Leaf, Elizabeth M., Park, Young-Jun, Asarnow, Daniel, Powers, John M., Treichel, Catherine, Sprouse, Kaitlin R., Corti, Davide et al. · 2024 · Nature Communications
  59. Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants
    Chu‐Wei Kuo, Tzu‐Jing Yang, Yu-Chun Chien, Pei‐Yu Yu, Shang‐Te Danny Hsu, Kay‐Hooi Khoo · 2021 · Glycobiology
  60. Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study
    S. Karuna, Shuying S. Li, S. Grant, S. Walsh, I. Frank, M. Casapia, M. Trahey, O. Hyrien, L. Fisher, Maurine D. Miner et al. · 2021 · PLoS Medicine
  61. SARS-CoV-2 Variants and Vaccination
    Yang Liu, Jianying Liu, Pei‐Yong Shi · 2022 · Zoonoses
  62. ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
    J. Seow, C. Graham, Sadie R. Hallett, T. Lechmere, T. Maguire, I. Huettner, D. Cox, Hataf Khan, S. Pickering, R. Roberts et al. · 2022 · Cell Reports
  63. CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity
    Yiru Long, Jianhua Sun, Tian‐Zhang Song, Tingting Liu, Feng Tang, Xinxin Zhang, Longfei Ding, Yunqiu Miao, Weiliang Zhu, Xiaoyan Pan et al. · 2022 · Cell Discovery
  64. Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders
    Jessica Denis, Annabelle Garnier, Laurence Cheutin, Audrey Ferrier, Hawa Timera, Fanny Jarjaval, Carine Garcia Hejl, Emmanuelle Billon-Denis, Percy ImmunoCovid group, Damien Ricard et al. · 2023 · Frontiers in Immunology
  65. Broadly neutralizing antibodies against COVID-19
    Daming Zhou, Jingshan Ren, Elizabeth E. Fry, David Ian Stuart · 2023 · Current Opinion in Virology
  66. Single-molecule imaging reveals allosteric stimulation of SARS-CoV-2 spike receptor binding domain by host sialic acid
    Marco Aurelio Díaz-Salinas, Aastha Jain, Natasha D. Durham, James B. Munro · 2024 · Science Advances
  67. Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans
    Amin Addetia, Cameron Stewart, Albert J. Seo, Kaitlin R. Sprouse, Ayed Y. Asiri, Maha Al-Mozaini, Ziad Ahmed Memish, Abeer N. Alshukairi, David Veesler · 2024 · Cell Reports
  68. Antigenic minimalism of SARS-CoV-2 is linked to surges in COVID-19 community transmission and vaccine breakthrough infections
    AJ Venkatakrishnan, Praveen Anand, Patrick J. Lenehan, Pritha Ghosh, Rohit Suratekar, Abhishek Siroha, Dibyendu Roy Chowdhury, John Charles O’Horo, Joseph D. C. Yao, Bobbi S. Pritt et al. · 2021 · medRxiv
  69. A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
    Shan, Sisi, Mok, Chee Keng, Zhang, Shuyuan, Lan, Jun, Li, Jizhou, Yang, Ziqing, Wang, Ruoke, Cheng, Lin, Fang, Mengqi, Aw, Zhen Qin et al. · 2021 · Frontiers in Immunology
  70. AIDS patient with severe T cell depletion achieved control but not clearance of SARS‐CoV‐2 infection
    Michele Spinicci, Alessio Mazzoni, Beatrice Borchi, Lucia Graziani, Marcello Mazzetti, Filippo Bartalesi, Annarita Botta, Marta Tilli, Filippo Pieralli, Marco Coppi et al. · 2021 · European Journal of Immunology
  71. Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy
    Amirmasoud Rayati Damavandi, Razieh Dowran, Sarah Al Sharif, Fatah Kashanchi, Reza Jafari · 2022 · Medical Microbiology and Immunology
  72. Insights into the structural peculiarities of the N-terminal and receptor binding domains of the spike protein from the SARS-CoV-2 Omicron variant
    Fatemeh Bayani, Negin Safaei Hashkavaei, Vladimir Nikolaevich Uversky, Sina Mozaffari‐Jovin, Yahya Sefidbakht · 2022 · Computers in Biology and Medicine
  73. Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults
    Patrick Yassini, Mark Hutchens, Yamuna Devi Paila, Lorraine Schoch, Anne Aunins, Umaporn Siangphoe, Robert Paris · 2023 · Human Vaccines & Immunotherapeutics
  74. Design of customized coronavirus receptors
    Peng Liu, Meiling Huang, Hua Guo, Matthew McCallum, Jun-Yu Si, Yuanmei Chen, Chunli Wang, Yu Xiao, Lulu Shi, Qing Xiong et al. · 2024 · Nature
  75. SARS-CoV-2 spike conformation determines plasma neutralizing activity
    John E. Bowen, Alexandra C. Walls, Anshu Joshi, Kaitlin R. Sprouse, Cameron Stewart, M. Alejandra Tortorici, Nicholas Franko, Jennifer K. Logue, Ignacio G. Mazzitelli, Sasha W. Tilles et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  76. Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries
    Asim Hussain, Hamza Rafeeq, Hafiza Memoona Asif, Sumaira Shabbir, Muhammad Bilal, Sikandar Imamsab Mulla, Marcelo Franco, Hafiz M.N. Iqbal · 2021 · International Immunopharmacology
  77. A rigorous framework for detecting SARS-CoV-2 spike protein mutational ensemble from genomic and structural features
    Saman Fatihi, Surabhi Rathore, Ankit Kumar Pathak, Deepanshi Gahlot, Mitali Mukerji, Nidhi Jatana, Lipi Thukral · 2021 · Current Research in Structural Biology
  78. In Vivo Electroporation of Plasmid DNA: A Promising Strategy for Rapid, Inexpensive, and Flexible Delivery of Anti-Viral Monoclonal Antibodies
    Silvère Pagant, Rachel A. Liberatore · 2021 · Pharmaceutics
  79. Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
    Fatima Amanat, Shirin Strohmeier, Philip S. Meade, Nicholas Dambrauskas, Barbara Mühlemann, Derek J. Smith, Vladimir I. Vigdorovich, D. Noah Sather, Lynda Coughlan, Florian Krammer · 2021 · PLoS Biology
  80. Defective ORF8 dimerization in SARS-CoV-2 delta variant leads to a better adaptive immune response due to abrogation of ORF8-MHC1 interaction
    Armi M Chaudhari, Indra Singh, Madhvi N. Joshi, Amrutlal K. Patel, Chaitanya G. Joshi · 2022 · Molecular Diversity
  81. The Comparison of Mutational Progression in SARS-CoV-2: A Short Updated Overview
    Abeer Asif, Iqra Ilyas, Mohammad Abdullah, Sadaf Sarfraz, Muhammad Mustafa, Arif Mahmood · 2022 · Journal of Molecular Pathology
  82. Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants
    Lingyan Cui, Tingting Li, Wenhui Xue, Sibo Zhang, Hong Wang, Hongjing Liu, Ying Gu, Ningshao Xia, Shaowei Li · 2024 · Viruses
  83. K18- and CAG-hACE2 Transgenic Mouse Models and SARS-CoV-2: Implications for Neurodegeneration Research
    Simona Dedoni, Valeria Avdoshina, Chiara Camoglio, Carlotta Siddi, Walter Fratta, María Scherma, Paola Fadda · 2022 · Molecules
  84. A phylogeny-based metric for estimating changes in transmissibility from recurrent mutations in SARS-CoV-2
    Damien Richard, Liam P. Shaw, Robert Lanfear, Russell B Corbett-Detig, Angie S. Hinrichs, Jakob McBroome, Yatish Turakhia, Mislav Acman, Christopher J. Owen, Cedric C.S. Tan et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  85. Increased lung cell entry of B.1.617.2 and evasion of antibodies induced by infection and BNT162b2 vaccination
    Prerna Arora, Amy Madeleine Kempf, Inga Nehlmeier, Anzhalika Sidarovich, Nadine Krüger, Luise Graichen, Anna-Sophie Moldenhauer, Martin Sebastian Winkler, Sebastian R. Schulz, Hans‐Martin Jäck et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  86. NMR Based SARS-CoV-2 Antibody Screening
    Marta V. Schoenle, Yang Li, Meng Yuan, Michael W. Clarkson, Ian A. Wilson, Wolfgang Peti, Rebecca Page · 2021 · Journal of the American Chemical Society
  87. Increased Frequency of Indels in Hypervariable Regions of SARS-CoV-2 Proteins—A Possible Signature of Adaptive Selection
    Arghavan Alisoltani, Lukasz Jaroszewski, Mallika Iyer, Arash Iranzadeh, Adam Godzik · 2022 · Frontiers in Genetics
  88. Case Report: Post-COVID-19 Vaccine Recurrence of Guillain–Barré Syndrome Following an Antecedent Parainfectious COVID-19–Related GBS
    Margherita Bellucci, Francesco Germano, Stefano Giuseppe Grisanti, Chiara Castellano, Francesco Tazza, Emanuela Maria Mobilia, Davide Visigalli, Giovanni Novi, Federico Massa, Silvia Rossi et al. · 2022 · Frontiers in Immunology
  89. On the Origins of Omicron’s Unique Spike Gene Insertion
    AJ Venkatakrishnan, Praveen Anand, Patrick J. Lenehan, Rohit Suratekar, Bharathwaj Raghunathan, Michiel J.M. Niesen, Venky Soundararajan · 2022 · Vaccines
  90. Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2
    Dongxia Wang, Jakub Baudys, Sarah H. Osman, John Robert Barr · 2023 · Analytical and Bioanalytical Chemistry
  91. A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection
    L. Adams, Laura A. VanBlargan, Zhuo-Ming Liu, P. Gilchuk, Hai-Yan Zhao, Rita E. Chen, S. Raju, Zhen-Lu Chong, Bradley M. Whitener, S. Shrihari et al. · 2023 · Cell Reports Medicine
  92. Persistent SARS-CoV-2 Infection with Accumulation of Mutations in a Patient with Poorly Controlled HIV Infection
    Tongai Gibson Maponga, Montenique Jeffries, Houriiyah Tegally, Andrew D. Sutherland, Eduan Wilkinson, Richard J. Lessells, Nokukhanya Msomi, Gert Uves van Zyl, Túlio de Oliveira, Wolfgang Preiser · 2022 · SSRN Electronic Journal
  93. Jointly modeling deep mutational scans identifies shifted mutational effects among SARS-CoV-2 spike homologs
    Hugh K. Haddox, Jared Galloway, Bernadeta Dadonaite, Jesse D. Bloom, Frederick A. Matsen IV, William S. DeWitt · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  94. Neutralizing antibodies reveal cryptic vulnerabilities and interdomain crosstalk in the porcine deltacoronavirus spike protein
    Du, Wenjuan, Debski-Antoniak, Oliver, Drabek, Dubravka, van Haperen, Rien, van Dortmondt, Melissa, van der Lee, Joline, Drulyte, Ieva, van Kuppeveld, Frank J. M., Grosveld, Frank, Hurdiss, Daniel L. et al. · 2024 · Nature Communications
  95. More Is Always Better Than One: The N-Terminal Domain of the Spike Protein as Another Emerging Target for Hampering the SARS-CoV-2 Attachment to Host Cells
    Sonia Di Gaetano, Domenica Capasso, Pietro Delre, Luciano Pirone, Michele Saviano, Emilia Maria Pedone, Giuseppe Felice Mangiatordi · 2021 · International Journal of Molecular Sciences
  96. Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19?
    Mariele Montanari, Barbara Canonico, Evelyn Nordi, Daniela Vandini, Simone Barocci, Serena Benedetti, Eugenio Carlotti, Loris Zamai · 2021 · Advances in Biological Regulation
  97. Emerging mutation patterns in SARS-CoV-2 variants
    David A. Ostrov, Glenn W. Knox · 2021 · Biochemical and Biophysical Research Communications
  98. Protein engineering responses to the COVID-19 pandemic
    Ching-Lin Hsieh, J. McLellan · 2022 · Current Opinion in Structural Biology
  99. Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses
    Qianqian Li, Li Zhang, Ziteng Liang, Nan Wang, Shuo Liu, Tao Li, Yuanling Yu, Qianqian Cui, Xi Wu, Jianhui Nie et al. · 2022 · Signal Transduction and Targeted Therapy
  100. SARS-CoV-2 Spike Protein Post-Translational Modification Landscape and Its Impact on Protein Structure and Function via Computational Prediction
    Buwen Liang, Yiying Zhu, Wenhao Shi, Can Ni, Bowen Tan, Shaojun Tang · 2023 · Research